Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

首页> 外文期刊>The Lancet >Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

【24h】

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

机译：干扰素Beta-1b，Lopinavir-ritonavir和利巴韦林的三重组合治疗Covid-19承认医院的患者：开放标签，随机，第2期试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.

机译：背景技术有效的抗病毒治疗对于解决2019年（Covid-19）大流行的冠状病毒疾病很重要。我们评估了干扰素β-1B，Lopinavir-ritonavir和利巴韦林治疗Covid-19患者的疗效和安全性。

著录项

来源
《The Lancet》 |2020年第10238期|共10页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial [J] . The Lancet . 2020,第10238期

机译：干扰素Beta-1b，Lopinavir-ritonavir和利巴韦林的三重组合治疗Covid-19承认医院的患者：开放标签，随机，第2期试验
2. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial [J] . Kris V Kowdley, Eric Lawitz, Israel Crespo, The Lancet . 2013,第9883期

机译：Sofosbuvir用聚乙二醇化干扰素Alfa-2a和利巴韦林治疗野性丙型肝炎患者（原子）：开放标签，随机，多元相2试验
3. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial [J] . Mizokami Masashi, Yokosuka Osamu, Takehara Tetsuo, The Lancet infectious diseases . 2015,第6期

机译：初治和先前接受过治疗的基因型1型丙型肝炎日本患者中的Ledipasvir和Sofosbuvir固定剂量联合或不联合利巴韦林治疗12周：一项开放标签，随机，3期试验
4. Predictability of Sustained Virological Response (SVR) in Patients with HCV/HIV Co-infection During Combination Therapy With Peginterferon Alfa-2A (40KD) (PEGASYS~R) Plus Ribavirin (COPEGUS~R) in the APRICOT Trial [C] . M. Rodriguez Torres, F.J. Torriani, E. Lissen International AIDS Conference . 2004

机译：HCV / HIV与Peginterferon Alfa-2a（40KD）（Pegasys〜R）加上利韦韦林（Copegus〜R）在杏试验期间HCV / HIV CONOMENT患者持续病毒学反应（SVR）的可预测性
5. Nutritional Risk in the Cancer Patient 65 and Older Undergoing Systemic Treatment via Phase I Clinical Trials [D] . Williams, Anna Cathy. 2019

机译：癌症患者65岁及以上经受I期临床试验的营养风险
6. Triple combination of interferon beta-1b lopinavir–ritonavir and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label randomised phase 2 trial [O] . Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, -1

机译：干扰素β-1b洛匹那韦–利托那韦和利巴韦林的三联组合治疗COVID-19住院患者：一项开放标签随机2期试验
7. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial [O] . Paul Y Kwo, Eric J Lawitz, Jonathan McCone, 2010

机译：BocePrevir的疗效，NS3蛋白酶抑制剂与Peginterferon Alfa-2b和Ribavirin联合治疗 - 幼型患者的基因型1丙型肝炎感染（Sprint-1）：开放标签，随机，多期相2试验

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅